Evaluation of the Body Slimming Effect of TCI904

Inclusion criteria

• Age ≥ 20
• BMI ≥ 23 or male body fat ≥ 25%, female body fat ≥ 30%.
• History of Atherosclerotic cardiovascular disease (including cerebrovascular disease, coronary heart disease, peripheral vascular disease) or Type 2 diabetes or have any of the following factors: Age Men ≥ 45 years, Women ≥ 55 years or amenorrhea, hypertension, hyperlipidemia (total cholesterol > 200 mg/dL or low-density lipoprotein cholesterol LDL-C > 130 mg/dL or triglyceride TG > 130 mg/dL), high-density lipoprotein cholesterol HDL-C < 40 mg/dL.
• If people have routinely taken drugs for lowering blood sugar, blood pressure or blood lipids, there is no significant dose change within three months (variation ≤ 20%).
• Volunteers who are willing to participate in and complete the trial plan after explaining by the researchers, and sign the consent form.

Exclusion criteria

• History of diabetic ketoacidosis.
• Medical records documented cerebrovascular disease, acute myocardial infarction or coronary artery bypass surgery or placement of coronary artery stents or peripheral vascular disease within the last 6 months.
• Known acute infectious illness within the past month with > 7 days of antibiotics.
• Known short-term use of steroids, NSAIDs, anti-rejection drugs, interferon, immunomodulators or changes in long-term doses due to any factors in the past month.
• Have used any weight loss drugs (including Orlistate, Lorcaserin, liraglutide) within the past three months.
• History of any cancer in the past 5 years or still receiving cancer treatment.
• Patients with abnormal liver function (GOT or GPT greater than 3 times the upper limit of normal) or known cirrhosis.
• Patients with abnormal kidney function (eGFR < 30 mL/min/1.73 m^2).
• Patients with a history of alcoholism.
• Have participated in any other interventional clinical research within the last month.
• Pregnant and lactating women.
• Known history of allergy to the test substance.
• Patients who are judged inappropriate by the trial host.